“PrEP Makes My Relationship Even More Normal:” The Discursive Production of Hope in the Context of HIV Pre-exposure Prophylaxis Among Young Adults with Partners Living with HIV Infection

Part of the Social Aspects of HIV book series (SHIV, volume 2)


This analysis is based on a series of in-depth interviews conducted in Northern California, United States, during a pilot study focusing on young peoples’ perspectives on sexual health, particularly as it relates to HIV. Among our sample, we interviewed HIV seronegative young men and women who were romantically involved with partners who were living with HIV (n = 9). In this analysis, we attend to the local and practical concerns of these participants and examine the ways in which they envisioned a new biomedical HIV prevention technology – PrEP – shaping their experience of serodiscordance. We explore the similarities and differences in the ways that young seronegative partners, both heterosexuals and gay, talk about their identity as a member of a serodiscordant couple. In particular, we foreground PrEP’s role in the production of hope as it emerged in the discourse of these youth. With PrEP – a highly effective HIV prevention strategy – some of the threatening meanings ascribed to the virus receded; in their place, language reflecting hope and optimism appeared. This phenomenon signals that PrEP, as part of a new wave of biomedical interventions, is shifting people’s relationship to HIV and, as a consequence, relationship dynamics and perceptions of serodiscordance are evolving.


Serodiscordant Couple Biomedical Intervention Serodiscordant Relationship Graffito Artist Sexual Connection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. AIDS Healthcare Foundation. (2014). An open letter to the Centers for Disease Control: what if you’re wrong about PrEP? AIDS Healthcare Foundation. Accessed 6 May 2015.
  2. Auerbach, J. D., & Hoppe, T. A. (2015). Beyond “getting drugs into bodies”: Social science perspectives on pre-exposure prophylaxis for HIV. Journal of the International AIDS Society, 18(4 Suppl 3), 19983.PubMedPubMedCentralGoogle Scholar
  3. Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., the Partners PrEP Study Team, et al. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine, 367(5), 399–410.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., the HPTN 052 Study Team, et al. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine, 365(6), 493–505.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Godfrey, C. (2015). Why we need PrEP: Four gay men share their views on the HIV prevention drug. Independent. Accessed 4 Aug 2015.
  6. Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. New York: Simon and Schuster.Google Scholar
  7. Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., the iPrEx Study Team, et al. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587–2599.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Jacobs, D. (2015). A PrEP users perspective. Paper presented at IAS2015: The International AIDS Society Conference, Vancouver, Canada.
  9. Jacoby, A. (1994). Felt versus enacted stigma: A concept revisited. Evidence from a study of people with epilepsy in remission. Social Science and Medicine, 38(2), 269–274.CrossRefPubMedGoogle Scholar
  10. Kippax S. (2010). Reasserting the social in a biomedical epidemic: The case of HIV-prevention. Presented at the workshop: Reframing the Social Dimensions of HIV in a Biomedicalised Epidemic: The Case of Treatment as Prevention. London: Overseas Development Institute.Google Scholar
  11. Koester, K. A., & Grant, R. M. (2015). Keeping our eyes on the prize: No new HIV infections with increased use of HIV pre-exposure prophylaxis. Clinical Infectious Disease, 61(10), 1604–1605.CrossRefGoogle Scholar
  12. Koester, K., Amico, R., Liu, A., McMahan, V., Hosek, S., Mayer, K., et al. (2014). Sex on PrEP: Qualitative findings from the iPrEx Open Label Extension (OLE) in the United States. Paper presented at AIDS2014: The International AIDS conference, Melbourne.Google Scholar
  13. Nguyen, V. K., Bajos, N., Dubois-Arber, F., O’Malley, J., & Pirkle, C. M. (2011). Remedicalizing an epidemic: From HIV treatment as prevention to HIV treatment is prevention. AIDS, 25(3), 291–293.CrossRefPubMedGoogle Scholar
  14. Patton, C. (1990). Inventing AIDS. New York: Routledge.Google Scholar
  15. Persson, A. (2008). Sero-silence and sero-sharing: Managing HIV in serodiscordant heterosexual relationships. AIDS Care, 20(4), 503–506.CrossRefPubMedGoogle Scholar
  16. Persson, A. (2013). Non/infectious corporealities: Tensions in the biomedical era of “HIV normalisation”. Sociology of Health & Illness, 35(7), 1065–1079.CrossRefGoogle Scholar
  17. Persson, A. (2015). “The world has changed”: Pharmaceutical citizenship and the reimagining of serodiscordant sexuality among couples with mixed HIV status in Australia. Sociology of Health & Illness, 38(3), 380–395.CrossRefGoogle Scholar
  18. Potts, A. (2004). Deleuze on Viagra (or, what can a “Viagra-body” do?). Body & Society, 10(1), 17–36.CrossRefGoogle Scholar
  19. Race, K. (2009). Pleasure consuming medicine: The queer politics of drugs. Durham: Duke University Press.CrossRefGoogle Scholar
  20. Richardson, R., Golden, S., & Hanssens, C. (2015). Ending and defending against HIV criminalization: A manual for advocates. Vol. 1: State and federal laws and prosecutions (2nd ed.). New York: The Center for HIV Law and Policy.Google Scholar
  21. Rosengarten, M. (2009). HIV interventions: Biomedicine and the traffic between information and flesh. Seattle: University of Washington Press.Google Scholar
  22. Rosengarten, M., & Michael, M. (2009). The performative function of expectations in translating treatment to prevention: The case of HIV pre-exposure prophylaxis, or PrEP. Social Science & Medicine, 69(7), 1049–1055.CrossRefGoogle Scholar
  23. Sidibé, M. (2011). Game changing year: 2011 World AIDS Day message. Geneva: UNAIDS.Google Scholar
  24. Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., the TDF2 Study Group, et al. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine, 367(5), 423–434.CrossRefPubMedGoogle Scholar
  25. Treichler, P. A. (1999). How to have theory in an epidemic: Cultural chronicles of AIDS. Durham: Duke University Press.Google Scholar
  26. Ware, N. C., Wyatt, M. A., Haberer, J. E., Baeten, J. M., Kintu, A., Psaros, C., et al. (2012). What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. Journal of Acquired Immune Deficiency Syndromes, 59(5), 463–468.CrossRefPubMedGoogle Scholar
  27. Watney, S. (1997). Policing desire: Pornography, AIDS and the media. Minneapolis: University of Minnesota Press.Google Scholar
  28. Young, I., Flowers, P., & McDaid, L. M. (2014). Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: Findings from a qualitative study in Scotland. BMJ Open, 4(11), e005717.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Center for AIDS Prevention StudiesUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations